← Back

Q32 Bio Inc

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Price · split & dividend adjusted
News & notes moving QTTB
QTTB▼2

Q32 Bio prices $200 million public offering

Q32 Bio has priced an underwritten public offering expected to raise approximately $200 million in gross proceeds. The clinical-stage biotechnology company is offering 6.03 million shares of common stock at $18.25 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase 4.93 million shares at $18.2499 each. The proceeds estimate assumes no exercise of the underwriters' 30-day option to purchase up to an additional 1.64 million shares. The offering is expected to close on July 16, with net proceeds used for working capital including research, clinical development and commercialization activities, focusing on advancing bempikibart into future clinical trials. The stock price increased about 2.6% on Tuesday during after-hours trading.
QTTB ▼
Seeking Alpha·43dRead more ▾
Biotech & Genomic Medicine▲

Q32 Bio Leads Biotech Gainers on Positive Phase 2 Hair Loss Trial Results

Q32 Bio led biotech gainers Monday with shares soaring over 90% after its Phase 2 SIGNAL-AA trial of Bempikibart in severe alopecia areata showed 40% of patients in the modified intent-to-treat group achieved 20% or less scalp hair loss by Week 36. The company plans a registration-directed program in the first half of 2027 and also announced a $200 million public offering. Agenus jumped over 82% after entering an $85 million private placement to fund its planned Phase 3 ROBBIN1 trial of botensilimab and balstilimab in MSS colon cancer, with first patient dosing expected in early 2027. Actuate Therapeutics gained over 23% following last month's news that its drug Elraglusib will be evaluated in the BEACON2 pediatric neuroblastoma trial. Galectin Therapeutics rose over 13% after reaching an FDA agreement on the primary endpoint for its Phase 3 study of Belapectin in MASH cirrhosis. Amwell and Shoulder Innovations each gained over 11% on no specific news, with Amwell expecting second-quarter revenue of $48 million to $52 million and Shoulder Innovations raising its full-year revenue guidance to between $65 million and $68 million.
QTTB ▲ACTU ▲AGEN ▲GALT ▲
Biotech & Genomic Medicine
RTTNews·44dRead more ▾
QTTB▲2

Q32 Bio Stock Skyrocketed Today on Promising Alopecia Trial Data

Shares of Q32 Bio soared after the company announced that its Phase 2a clinical trial of bempikibart for severe alopecia areata met its primary efficacy goal, showing a 35% average reduction in scalp hair loss severity with no serious treatment-related adverse events. Oppenheimer analyst Jay Olson doubled his price target to $40 and reiterated an outperform rating, while Wells Fargo analyst Derek Archila set a $66 target, citing improved odds of success. The stock pulled back about 7% in after-hours trading after Q32 Bio announced a $200 million stock offering to fund further trials.
QTTB ▲
Motley Fool·44dRead more ▾
© 2026 MarketDXAsset